Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
3 July 2025
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
23 May 2025
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
22 May 2025
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
22 May 2025
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
21 May 2025
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
21 May 2025
Starglo isn't applicable to a US population, an adcom rules.
20 May 2025
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.